www.fdanews.com/articles/70064-amylin-receives-approval-for-diabetes-drug-symlin
Amylin Receives Approval for Diabetes Drug Symlin
March 21, 2005
Amylin Pharmaceuticals has received FDA approval for Symlin (pramlintide acetate) injection to be used in conjunction with insulin to treat diabetes.
The company said the drug will be commercially available in approximately 90 days. Symlin is intended for patients with Type 1 or Type 2 diabetes who have failed to achieve desired glucose control despite optimal insulin therapy.